GO
Loading...

Biotech Analyst Bullish on BIIB

Monday, 20 Jun 2011 | 5:41 PM ET

Mark Schoenebaum, ISI Group analyst, explains how BIIB can triple its dividend in three years. "This growth exists nowhere else in large cap pharma or biotech," he says.